Table 3 Comparison of baseline values and lung function changes after treatment according to the radiologic classification
From: Long-term clinical course and outcomes of immunoglobulin G4-related lung disease
Total | Alveolar consolidative | Solid nodular | Bronchovascular | Alveolar interstitial | Round ground glass opacity | |
|---|---|---|---|---|---|---|
Number of patients | 22 | 5 | 5 | 7 | 4 | 1 |
FVC at diagnosis, %pred | 80.4 ± 16.3 | 72.8 ± 25.4 | 93.6 ± 8.0 | 90.1 ± 11.7 | 71.3 ± 3.4 | 101.0 |
FEV1 at diagnosis, %pred | 81.1 ± 17.5 | 72.0 ± 21.3 | 91.2 ± 17.4 | 82.7 ± 14.9 | 83.8 ± 18.7 | 90.0 |
FEV1/FVC at diagnosis | 76.0 ± 12.3 | 78.2 ± 20.3 | 76.4 ± 7.4 | 72.0 ± 7.2 | 82.0 ± 14.4 | 67.0 |
DLCO at diagnosis, %pred | 73.7 ± 22.5 | 64.8 ± 15.8 | 91.6 ± 12.8 | 78.3 ± 15.6 | 55.3 ± 21.1 | 93.0 |
TLC at diagnosis, %pred | 85.6 ± 14.0 | 77.3 ± 14.9 | 98.7 ± 11.7 | 82.3 ± 11.0 | 78.0 ± 3.5 | 96.0 |
ΔFVC at 1 year, % | 8.9 ± 11.6 | 19.1 ± 15.5 | 0.4 ± 1.6 | 3.9 ± 9.3 | 15.2 ± 7.1 | 0.0 |
ΔFEV1 at 1 year, % | 5.5 ± .2 | 10.2 ± 15.5 | 2.5 ± 3.6 | 4.2 ± 12.2 | 7.4 ± 4.4 | -2.2 |
ΔFEV1/FVC at 1 year, % | − 3.8 ± 9.6 | − 7.9 ± 5.3 | − 1.2 ± 6.8 | 2.8 ± 7.6 | − 13.3 ± 13.1 | − 4.5 |
ΔDLCO at 1 year, % | 3.9 ± 16.0 | 8.9 ± 31.1 | − 0.4 ± 8.2 | 11.2 ± 10.8 | 1.5 ± 9.0 | 0.0 |
ΔTLC at 1 year, % | 1.8 ± 8.5 | 11.1 ± 12.5 | − 2.9 ± 3.1 | − 1.6 ± 2.3 | 0.9 ± 8.7 | 3.1 |